Laboratório de Inflamação, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Br J Pharmacol. 2011 Apr;162(8):1674-85. doi: 10.1111/j.1476-5381.2010.01086.x.
Prostaglandin (PG) D(2) has emerged as a key mediator of allergic inflammatory pathologies and, particularly, PGD(2) induces leukotriene (LT) C(4) secretion from eosinophils. Here, we have characterized how PGD(2) signals to induce LTC(4) synthesis in eosinophils.
Antagonists and agonists of DP(1) and DP(2) prostanoid receptors were used in a model of PGD(2) -induced eosinophilic inflammation in vivo and with PGD(2) -stimulated human eosinophils in vitro, to identify PGD(2) receptor(s) mediating LTC(4) secretion. The signalling pathways involved were also investigated.
In vivo and in vitro assays with receptor antagonists showed that PGD(2) -triggered cysteinyl-LT (cysLT) secretion depends on the activation of both DP(1) and DP(2) receptors. DP(1) and DP(2) receptor agonists elicited cysLTs production only after simultaneous activation of both receptors. In eosinophils, LTC(4) synthesis, but not LTC(4) transport/export, was activated by PGD(2) receptor stimulation, and lipid bodies (lipid droplets) were the intracellular compartments of DP(1) /DP(2) receptor-driven LTC(4) synthesis. Although not sufficient to trigger LTC(4) synthesis by itself, DP(1) receptor activation, signalling through protein kinase A, did activate the biogenesis of eosinophil lipid bodies, a process crucial for PGD(2) -induced LTC(4) synthesis. Similarly, concurrent DP(2) receptor activation used Pertussis toxin-sensitive and calcium-dependent signalling pathways to achieve effective PGD(2) -induced LTC(4) synthesis.
Based on pivotal roles of cysLTs in allergic inflammatory pathogenesis and the collaborative interaction between PGD(2) receptors described here, our data suggest that both DP(1) and DP(2) receptor antagonists might be attractive candidates for anti-allergic therapies.
前列腺素(PG)D(2)已成为过敏炎症性病变的关键介质,特别是 PGD(2)诱导嗜酸性粒细胞释放白三烯(LT)C(4)。在这里,我们描述了 PGD(2)如何信号诱导嗜酸性粒细胞合成 LTC(4)。
使用 DP(1)和 DP(2)前列腺素受体的拮抗剂和激动剂,在体内 PGD(2)诱导的嗜酸性粒细胞炎症模型中和体外 PGD(2)刺激的人嗜酸性粒细胞中,鉴定介导 LTC(4)分泌的 PGD(2)受体。还研究了涉及的信号通路。
体内和体外的受体拮抗剂实验表明,PGD(2)触发的半胱氨酰-LT(cysLT)分泌依赖于 DP(1)和 DP(2)受体的激活。DP(1)和 DP(2)受体激动剂仅在同时激活两种受体后才会引起 cysLTs 的产生。在嗜酸性粒细胞中,LTC(4)的合成,而不是 LTC(4)的转运/输出,是由 PGD(2)受体刺激激活的,脂滴(脂质滴)是 DP(1)/DP(2)受体驱动的 LTC(4)合成的细胞内隔室。尽管 DP(1)受体的激活本身不足以触发 LTC(4)的合成,但通过蛋白激酶 A 信号转导,激活了嗜酸性粒细胞脂滴的生物发生,这是 PGD(2)诱导 LTC(4)合成所必需的过程。同样,同时激活 DP(2)受体利用百日咳毒素敏感和钙依赖性信号通路来实现有效的 PGD(2)诱导的 LTC(4)合成。
鉴于 cysLTs 在过敏炎症发病机制中的重要作用以及本文所述的 PGD(2)受体之间的协同相互作用,我们的数据表明,DP(1)和 DP(2)受体拮抗剂都可能是抗过敏性治疗的有吸引力的候选药物。